Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations

Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will make them no longer worthwhile for the company, according to...